
    
      This is a Phase I trial of S-1 given in treatment days with an oral dose from 30mg/m2/d to
      80mg/m2/d, concurrently with radiation in patients with locally advanced or locally recurrent
      gastric cancer. Patients will be treated with external beam radiation therapy in a standard
      manner. S-1 will be administered for 6 dose levels,30/40/50/60/70/80mg/m2/d. Patients will be
      assessed for acute toxicities according to Common Toxicity Criteria for Adverse Effects
      (CTCAE)3.0.
    
  